| 1004 |
White Matter Hyperintensities and Cognitive Functions in People With the R544C Variant of the NOTCH3 Gene Without Stroke or Dementia
|
2024-11-01 |
104 |
| 1003 |
Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack
|
2024-11-01 |
140 |
| 1002 |
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
|
2024-11-01 |
146 |
| 1001 |
Asundexian versus Apixaban in Patients with Atrial Fibrillation
|
2024-09-27 |
193 |
| 1000 |
Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis The BASIS Randomized Clinical Trial
|
2024-09-27 |
175 |
| 999 |
Thrombectomy for Stroke With Large Infarct on Noncontrast CT : The TESLA Randomized Clinical Trial
|
2024-09-27 |
188 |
| 998 |
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core
|
2024-08-28 |
310 |
| 997 |
Efficacy and Safety of High-Dose TBS on Poststroke Upper Extremity Motor Impairment: A Randomized Controlled Trial
|
2024-08-28 |
295 |
| 996 |
Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial
|
2024-08-28 |
308 |
| 995 |
HERMES-24 Score Derivation and Validation for Simple and Robust Outcome Prediction After Large Vessel Occlusion Treatment
|
2024-07-30 |
313 |
| 994 |
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial
|
2024-07-30 |
336 |
| 993 |
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy
|
2024-07-30 |
317 |
| 992 |
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants
|
2024-07-01 |
396 |
| 991 |
Reteplase versus Alteplase for Acute Ischemic Stroke
|
2024-07-01 |
332 |
| 990 |
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia
|
2024-07-01 |
326 |
HOME
LOGIN
